The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Abstract
We read the Parkinson Study Group’s article with interest.1 The disappointing result in PRECEPT that used mixed-lineage kinase (MLK) inhibitor CEP-1347 for treatment of Parkinson disease (PD) may be because 1) the hypothesis that MLK inhibitors retard disease progression is incorrect; 2) the inhibitor does not reach therapeutic levels in the CNS; or 3) MLK inhibitors require an additional signal to maintain dopaminergic neuronal survival. Based on our research into the molecular mechanism of MLK inhibitors, we propose the third possibility as why MLK inhibitors did not maintain neuronal survival. Small-molecule MLK inhibitors such as CEP-1347 and CEP-11004 inhibit activation of the c-Jun NH2-terminal kinase (JNK) and neuronal cell death pathway in many cell culture and animal models. However, in three well-defined cell culture models of trophic factor-withdrawal neuronal cell death, neurons maintained by MLK inhibitors require additional activation of the phosphatidylinositol 3-kinase (PI3-kinase) pathway for survival.2,3 In sympathetic neurons deprived of nerve growth factor, MLK inhibitors induce TrkA receptor overexpression.3 Increases in TrkA expression cause ligand-independent activation of the receptor and, consequently, the PI3-kinase-Akt-GSK (glycogen synthase kinase)-3 pathway. Inhibition of PI3-kinase negates the long-term cell survival and trophic effects of MLK inhibitors. In contrast, MLK inhibitors only maintain short-term survival in trophic-deprived cerebellar granule neurons (CGNs) that express TrkB, another Trk-receptor family member. While MLK inhibitors increase TrkB expression, this does …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Morón, J. A., Zakharova, I., Ferrer, J. V., Merrill, G. A., Hope, B., Lafer, E. M., Lin, Z. C., Wang, J. B., Javitch, J. A., Galli, A., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08480.2003 · Cited by 262
Cited by
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
Metadata
- Authors
- Wang, L. H., & Johnson, E. M.
- Venue
- Neurology
- Published
- 2008-08-05
- Volume
- 71
- Issue
- 6
- Pages
- 462-463
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2081972226
- Cited by
- 204
- References
- 3
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE. https://app.cochat.ai/papers/10.1212/01.wnl.0000324506.93877.5e
- The paper
- Wang, L. H., & Johnson, E. M. (2008). MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE. Neurology. https://doi.org/10.1212/01.wnl.0000324506.93877.5e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.